Result of AGM

RNS Number : 1528N
Oxford Biomedica PLC
27 May 2022
 

 

 

 

Oxford Biomedica

Result of Annual General Meeting

 

Oxford, UK - 27 May 2022: Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica" or "the Company") , a leading gene and cell therapy group, announces today that all resolutions proposed were duly passed at its Annual General Meeting (AGM), held at 3pm on 27 May 2022 in Oxford. As proposed in the Notice of AGM, all resolutions were decided by poll vote.

 

The full text of all the resolutions can be viewed in the Notice of Meeting by visiting the Company's website at www.oxb.com

 

Copies of the document setting out the above resolutions passed at the 2022 AGM have been submitted to the National Storage Mechanism and will shortly be available for inspection at: https://data.fca.org.uk/#/nsm/nationalstoragemechanism

 

On the Record Date (25 May 2022) there were 96,063,479 ordinary shares of 50 pence each in issue, each carrying one vote per share.

 

 

 

 

 

 

 

Resolution

 

Votes

For (incl. votes at the Chairman's discretion)

Votes at

other proxy

Discretion

 

Votes

Against

 

Votes

Withheld*

 

Total

votes cast

Result

 

 

 

 

 

 

 

 

 

Ordinary resolutions














1

 

 

 

 

 

 

 

 

 

To receive the Company's  Accounts, the Reports of the Directors and Auditor and the Strategic Report for the year ended 31 December 2021.

71,533,247

(99.99%)

 

 

 

 

 

 

 

 

0

3,804

(0.01%)

 

 

 

 

 

 

 

 

907,786

 

 

 

 

 

 

 

 

 

71,537,051

 

 

 

 

 

 

 

 

 

Passed

 









2

 

 

 

 

 

 

 

 

 

To receive the Directors' Remuneration Report and the Report of the Auditor on the Remuneration Report for the year ended 31 December 2021.

57,808,878

(80.73%)

 

 

 

 

 

 

 

 

0

13,801,220

(19.27%)

 

 

 

 

 

 

 

 

834,739

 

 

 

 

 

 

 

 

 

71,610,098

 

 

 

 

 

 

 

 

 

Passed

 









3

 

 

To appoint Dr. Michael Hayden as a Director.

62,539,719

(87.06%)

 

0

9,295,954

(12.94%)

 

609,164

 

 

71,835,673

 

 

Passed

 









4

 

 

 

To appoint Catherine Moukheibir as a Director.

71,748,494

(99.88%)

 

 

0

86,921

(0.12%)

 

 

609,422

 

 

 

71,835,415

 

 

 

Passed

 









5

 

 

To appoint Namrata P. Patel as a Director.

71,746,512

(99.88%)

 

0

88,903

(0.12%)

 

609,422

 

 

71,835,415

 

 

Passed

 









6

 

 

To reappoint Dr. Roch Doliveux as a Director.

68,788,280

(96.81%)

 

0

2,264,491

(3.19%)

 

1,392,066

 

 

71,052,771

 

 

Passed

 









7

 

 

 

To reappoint Professor Dame Kay Davies as a Director.

69,259,453

(96.41%)

 

 

0

2,575,962

(3.59%)

 

 

609,422

 

 

 

71,835,415

 

 

 

Passed

 









8

 

 

To reappoint Dr. Siyamak Rasty as a Director.

71,719,604

(99.84%)

 

0

116,069

(0.16%)

 

609,164

 

 

71,835,673

 

 

Passed

 









9

 

 

To reappoint Stuart Paynter as a Director.

71,206,012

(99.12%)

 

0

629,661

(0.88%)

 

609,164

 

 

71,835,673

 

 

Passed

 









10

 

 

To reappoint Stuart Henderson as a Director.

67,003,486

(93.27%)

 

0

4,832,187

(6.73%)

 

609,164

 

 

71,835,673

 

 

Passed

 









11

 

 

To reappoint Dr. Heather Preston as a Director

64,708,975

(90.08%)

 

0

7,126,698

(9.92%)

 

609,164

 

 

71,835,673

 

 

Passed

 

 









12

 

 

To reappoint Robert Ghenchev as a Director.

71,526,110

(99.57%)

 

0

309,305

(0.43%)

 

609,422

 

 

71,835,415

 

 

Passed

 

 









13

 

 

To reappoint KMPG LLP as auditor.

71,831,890

(99.99%)

 

0

 

 

7,494

(0.01%)

 

605,453

 

 

71,839,384

 

 

Passed

 

 









14

 

 

 

To authorise the Directors to agree the remuneration of the auditor.

71,832,849

(99.99%)

 

 

0

 

 

 

6,921

(0.01%)

 

 

605,067

 

 

 

71,839,770

 

 

 

Passed

 

 

 









15

 

 

To authorise the Directors to allot shares.

67,355,882

(93.77%)

 

0

 

 

4,471,767

(6.23%)

 

617,188

 

 

71,827,649

 

 

Passed

 

 

 

 

Special resolutions














16

 

 

 

To authorise the Directors to disapply pre-emption rights.

70,888,310

(98.70%)

 

 

0

937,061

(1.30%)

 

 

619,466

 

 

 

71,825,371

 

 

 

Passed

 

 

 









17

 

 

 

 

 

 

To authorise the Directors to further disapply pre-emption rights for acquisitions and specified capital investments.

70,922,796

(98.74%)

 

 

 

 

 

0

903,407

(1.26%)

 

 

 

 

 

618,634

 

 

 

 

 

 

71,826,203

 

 

 

 

 

 

Passed

 

 

 

 

 

 









18

 

 

 

 

 

 

 

To permit the Directors to convene general meetings (other than annual general meetings) on not less than 14 days' notice.

69,350,429

(96.53%)

0

2,489,321

(3.47%)

605,087

71,839,750

 

 

 

 

 

 

 

Passed

 

 

 

 

 

 

 

 

* A vote withheld is not a vote in law and is not counted towards votes cast in respect of a resolution.

 

In addition, further to the announcements by the Company in January and April, John Dawson has stepped down from the Company's Board of Directors after more than thirteen years of service with effect from the conclusion of today's AGM.

 

 

-Ends-

 

 

Enquiries: 

 

Oxford Biomedica plc: T: +44 (0)1865 783 000 / E: ir@oxb.com

Stuart Paynter, Chief Financial Officer

Sophia Bolhassan, Head of Investor Relations

Consilium Strategic Communications:

T: +44 (0)20 3709 5700 / E: oxfordbiomedica@consilium-comms.com

 

Mary-Jane Elliott / Matthew Neal / Matthew Cole

 

 

About Oxford Biomedica

Oxford Biomedica (LSE:OXB) is an innovative leading viral vector specialist focused on delivering life changing therapies to patients.

 

Oxford Biomedica plc and its subsidiaries (the Group) work across key viral vector delivery systems including those based on lentivirus, adeno-associated virus (AAV) and adenovirus, providing innovative solutions to cell and gene therapy biotechnology and biopharma companies for their process development, analytical development and manufacturing needs. Oxford Biomedica has built a sector leading lentiviral vector delivery system, LentiVector® platform, which the Group leverages to develop product candidates in-house, before seeking partners to take the products into clinical trials.

 

Oxford Biomedica is based across several locations and headquartered in Oxfordshire, UK. In early 2022, the Group established Oxford Biomedica Solutions, a new US based subsidiary AAV manufacturing and innovation business, based near Boston, US.

 

Oxford Biomedica employs more than 940 people. Further information is available at www.oxb.com .

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RAGSEUFMWEESEII
UK 100

Latest directors dealings